Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).
In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
ER+HER2- breast cancer
Premenopausal and age <=50
T1 or T2
N1 including micrometastasis
Postmenopausal women
ER-negative breast cancer
Single group
Ovarian function suppression with endocrine treatments
Drug* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years. * Either goserelin acetate or leuprorelin Acetate is allowed. * These patients are able to choose bilateral salpingo-oophorectomy instead of OFS. * Chemotherapy is omitted in these patients.
Distant recurrence-free survival
The interval between the date of primary surgery and the date of last censored, or distant recurrence or death of any cause
Recurrence-free survival (RFS)
The interval between the date of primary surgery and the date of last censored, or any type of recurrence or death of any cause
Invasive disease-free survival (iDFS)
The interval between the date of primary surgery and the date of last censored, or any type of invasive disease except thyroid cancer or death of any cause
Click on the lead sponsor to view all of their trials.
Gangnam Severance Hospital
Lead sponsor
Seoul National University
Collaborator
